Anika Therapeutics (ANIK) Cash & Equivalents (2010 - 2026)
Anika Therapeutics (ANIK) posted quarterly Cash & Equivalents of $38.4 million for Q2 2026, down 27.75% year-over-year from $53.2 million in Q2 2025, and down 6.36% quarter-over-quarter from $41.0 million in Q1 2026.
Anika Therapeutics (ANIK) Cash & Equivalents (2010 - 2026) Analysis & Trends
Anika Therapeutics (ANIK) has reported Cash & Equivalents for 17 consecutive years, with $38.4 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Cash & Equivalents fell 27.75% year-over-year to $38.4 million; the TTM figure through Jun 2026 stood at $38.4 million (down 27.75% YoY), while the FY2025 annual figure was $57.5 million, up 3.33% from the prior year.
- Cash & Equivalents slipped to $38.4 million in Q2 2026 per ANIK's latest filing, from $41.0 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $91.4 million in Q2 2022 and bottomed at $38.4 million in Q2 2026.
- Historically, Cash & Equivalents has averaged $66.2 million across 5 years, with a median of $63.9 million in 2023.
- Annual changes were most pronounced in 2023 — Cash & Equivalents declined 28.8% — and 2025, when it gained 3.33%.
- Anika Therapeutics' Cash & Equivalents stood at $86.3 million in 2022, then decreased by 20.37% to $68.7 million in 2023, then decreased by 19.07% to $55.6 million in 2024, then rose by 3.33% to $57.5 million in 2025, then tumbled by 33.17% to $38.4 million in 2026.
- Business Quant data shows ANIK's Cash & Equivalents at $38.4 million in Q2 2026, $41.0 million in Q1 2026, and $57.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 1.11 Bn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 1.48 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 2.89 Bn |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn | 1.80 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 332.40 Mn |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 164.00 Mn |
| 10 | Anika Therapeutics | 282.86 Mn | 244.45 Mn | 21.24 Mn | 38.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 38.41 Mn |
| Mar 31, 2026 | 41.02 Mn |
| Dec 31, 2025 | 57.48 Mn |
| Sep 30, 2025 | 57.99 Mn |
| Jun 30, 2025 | 53.17 Mn |
| Mar 31, 2025 | 53.37 Mn |
| Dec 31, 2024 | 55.63 Mn |
| Sep 30, 2024 | 62.37 Mn |
| Jun 30, 2024 | 62.82 Mn |
| Mar 31, 2024 | 68.63 Mn |
| Dec 31, 2023 | 68.74 Mn |
| Sep 30, 2023 | 70.65 Mn |
| Jun 30, 2023 | 65.07 Mn |
| Mar 31, 2023 | 79.74 Mn |
| Dec 31, 2022 | 86.33 Mn |
| Sep 30, 2022 | 87.78 Mn |
| Jun 30, 2022 | 91.39 Mn |
| Mar 31, 2022 | 90.33 Mn |
| Dec 31, 2021 | 94.39 Mn |
| Sep 30, 2021 | 90.98 Mn |